Saturday 17 October 2026 Export SBFM’s income statement to Excel — free account

Sunshine Biopharma, Inc.

SBFM Healthcare Drug Manufacturers Specialty & Generic

Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024. In the quarter to June 2026, revenue fell 1.56%, EPS grew 70.5% and free cash flow grew 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

0.22 0.01 −4.35%

Follow SBFM

Alert me

Market cap: $990.0K
P/E: 0.0×
Fwd P/E: −0.4×
Dividend yield: —
F-score: 4/9
Altman Z: −1.72
Beneish M: −2.96
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 0.99

Revenue 35.35

Net Income (5.83)

Free Cash Flow (5.54)

Net Debt (13.75)

Current Ratio 5.46

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.39)

P/S ratio 0.01

P/B ratio 0.01

Past 5Y EPS Growth —

This Y EPS Growth 86.46%

Next Y EPS Growth 79.49%

Next Y revenue growth 1.22%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.37%

10-year low 10-year high

P/B against its own 10 years 3.31%

10-year low 10-year high

EV/FCF against its own 10 years 87.74%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	16	10	9	14
Receivables	3	4	3	4
Inventory	6	11	13	12
Other	—	—	—	0
	25	26	27	31

	2023	2024	2025	Q'26
Payables	3	6	6	5
ST’ Debt	—	—	—	—
Other	—	—	—	—
	6	6	6	6

Compound Annual Growth %

	10y	5y	3y
Sales	—	247.74%	102.91%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	2.13%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	8	9	—	—	—
’25	9	9	9	9	36
’24	8	9	8	10	35
’23	5	6	6	8	24
’22	0	0	0	4	4
’21	0	0	0	0	0
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(1)	—	—	—
’25	(2)	(1)	(1)	(2)	(5)
’24	(3)	(5)	(1)	(3)	(13)
’23	(2)	(4)	0	(3)	(9)
’22	(1)	(1)	(1)	(2)	(5)
’21	0	(1)	(1)	0	(2)
’20	0	0	0	0	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(1)	—	—	—
’25	(2)	(2)	(1)	(2)	(6)
’24	(4)	(5)	(2)	(4)	(15)
’23	(2)	(4)	0	(3)	(10)
’22	(1)	(1)	(1)	(3)	(6)
’21	0	(1)	(1)	0	(2)
’20	0	0	0	0	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.50)	(1.15)	—	—	—
’25	(4.40)	(3.90)	(1.90)	(4.60)	(14.40)
’24	(20.02)	(99.40)	(9.40)	55.71	(73.20)
’23	(1.60k)	(711.72)	(501.14)	(1.00k)	(3.80k)
’22	(4.60k)	(600.00)	(1.60k)	(30.00k)	(35.20k)
’21	(56.38k)	(24.07k)	(31.77k)	16.99k	(95.20k)
’20	(50.15)	(118.57)	(49.74)	(54.37k)	(54.59k)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3,333,333.25	3,316,666.75	500,000.00	24,000.00	5,200.00	60,000.00	12,400.00	4,100.00	21.06	11.60	Analyst estimates 2026–2028 Powerpack
	High	62,500,000.00	46,666,668.00	29,166,666.00	2,400,000.00	3,778,000.00	1,256,000.00	310,000.00	28,000.00	5,820.00	39.00
People
People	Employees	3	3	9	3	3	3	46	44	52	50
	Revenue/emp, $m	0.00	0.00	0.00	0.01	0.02	0.08	0.09	0.55	0.67	0.73
Income, $m
Income, $m	Revenue	—	—	—	0	0	0	4	24	35	36
	Gross margin, %	0.00	0.00	0.00	47.87	63.87	48.42	39.04	34.61	30.60	33.76
	EBT	(3)	(1)	(2)	(1)	(3)	(12)	(27)	(4)	(5)	(6)
	EBT margin, %	0.00	0.00	0.00	(5,109.48)	(3,899.30)	(5,445.05)	(610.07)	(17.06)	(15.40)	(16.40)
	Net income	(3)	(1)	(2)	(2)	(3)	(12)	(27)	(5)	(5)	(6)
	Depreciation	1	0	0	0	0	0	18	0	0	2
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	42.20	714.00	2,284.00	5,432.00	18,532.92	496.78	87.34
	Earnings	(164.60)	(476.80)	(14,153.54)	(3,037.26)	(54,590.02)	(95,200.00)	(35,200.00)	(3,800.00)	(73.20)	(14.40)
	Cash flow	(14.82)	(247.05)	(2,564.00)	(991.60)	(6,573.00)	(18,291.00)	(6,560.50)	(6,750.08)	(178.42)	(12.82)
	Capex	(0.16)	(1.68)	(94.50)	(1.80)	(12.00)	0.00	(381.25)	(606.23)	(28.20)	(2.01)
	Free cash flow	(14.98)	(248.73)	(2,658.50)	(993.40)	(6,585.00)	(18,291.00)	(6,941.75)	(7,356.31)	(206.61)	(14.84)
	Book value	(9.89)	(260.64)	(279.00)	(1,470.80)	(9,548.00)	2,117.00	27,034.50	16,313.38	334.77	55.42
	Shares, m	0	0	0	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	853.08	87.96	102.32	2.74	0.30	0.06	0.14
	P/B	—	—	—	0.00	0.00	209.31	0.55	0.34	0.09	0.22
	EV/Sales	—	—	—	867.10	87.38	101.68	(1.84)	(0.30)	(0.16)	(0.06)
	EV/FCF	—	—	—	(37.06)	(9.45)	(12.68)	1.47	0.76	0.39	0.34
Cash, $m
Cash, $m	Operating cash flow	0	(1)	(1)	0	(1)	(2)	(5)	(9)	(13)	(5)
	Capex	0	0	0	0	0	—	0	(1)	(2)	(1)
	Free cash flow	0	(1)	(1)	0	(1)	(2)	(6)	(10)	(15)	(6)
Balance, $m
Balance, $m	Working capital	0	(1)	0	(1)	0	2	20	19	20	20
	Total debt	0	0	0	1	1	2	1	—	—	—
	Net debt	0	0	0	0	0	0	(22)	(16)	(10)	(9)
	Shareholders’ equity	0	(1)	0	(1)	(1)	0	22	21	24	23
Returns, %
Returns, %	ROA	(948.00)	(646.29)	(307.13)	(266.78)	(486.90)	(765.70)	(170.09)	(15.92)	(17.73)	(19.71)
	ROIC	0.00	0.00	(589.22)	0.00	0.00	(2,293.33)	0.00	(60.85)	(26.30)	(27.97)
	ROE	771.30	235.58	591.39	372.60	302.59	2,637.37	(246.06)	(21.04)	(22.97)	(25.69)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
AKAN Akanda Corp.	$3.5M	—	—	—	—	−472.01% (below 0%: shrinking)	(197.87%)	0.00%	Compare
PRFX PainReform Ltd.	$2.6M	— (loss-making)	— (loss-making)	—	n/m	+52.56% (above 0%: growing)	0.00%	0.00%	Compare
BTAIQ BioXcel Therapeutics, Inc.	$2.3M	— (loss-making)	— (loss-making)	+51.67% (above 0%: growing)	n/m	+51.51% (above 0%: growing)	87.91%	(5,600.55%)	Compare
IMCC IM Cannabis Corp.	$2.2M	— (loss-making)	— (loss-making)	−40.28% (below 0%: shrinking)	n/m	−266.81% (below 0%: shrinking)	19.83%	(27.54%)	Compare
NEPTF Neptune Wellness Solutions Inc.	$1.6M	— (loss-making)	— (loss-making)	−37.75% (below 0%: shrinking)	n/m	+53.44% (above 0%: growing)	13.62%	(232.88%)	Compare
PTPI Petros Pharmaceuticals, Inc.	$1.0M	— (loss-making)	— (loss-making)	+1,070.55% (above 0%: growing)	n/m	+71.27% (above 0%: growing)	73.82%	0.00%	Compare
SBFM Sunshine Biopharma, Inc.	$990.0K	— (loss-making)	— (loss-making)	−1.56% (below 0%: shrinking)	n/m	+49.38% (above 0%: growing)	26.20%	(17.41%)
LSDIF Lucy Scientific Discovery Inc.	$900.0K	— (loss-making)	—	—	n/m	−493.98% (below 0%: shrinking)	59.79%	(8,891.75%)	Compare
SXTC China SXT Pharmaceuticals, Inc.	$710.0K	— (loss-making)	— (loss-making)	−16.76% (below 0%: shrinking)	+92.67% (above 0%: growing)	−107.59% (below 0%: shrinking)	44.09%	0.00%	Compare
Median of peers	$1.9M	—	—	−16.76%	—	−28.04%	31.96%	(13.77%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Sunshine Biopharma, Inc. (SBFM) key facts

Strength: Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024.
Sunshine Biopharma, Inc. (SBFM) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, SBFM traded at $0.22, a market capitalization of $990,000.00.
Return on equity was −25.7% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −1.72 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.